Table 1 Patient, tumor, and treatment characteristics
N (%) or Median [IQR] | ||
|---|---|---|
Age | 51.0 [45.0–57.0] | |
Subtype of breast tumor | HR positive/HER2 negative | 48 (36.1) |
HR positive/HER2 positive | 19 (14.3) | |
HR negative/HER2 positive | 19 (14.3) | |
TN | 47 (35.3) | |
Disease extent at initial breast cancer diagnosis | ||
Lymph node | 49 (36.8) | |
Liver | 23 (17.3) | |
Lung | 52 (39.1) | |
Bone | 65 (48.9) | |
Brain | 1 (0.8) | |
Treatment era | 2010–2015 | 52 (39.1) |
2016–2021 | 81 (60.9) | |
Numbers of previous systemic treatments (lines) | 2 [1–4] | |
Systemic treatment-free interval (months) | 0.8 [0.0–1.2] | |
Number of metastatic lesions | Oligometastasis (≤ 5 lesions) | 13 (9.8) |
Polymetastasis (> 5 lesions) | 120 (90.2) | |
Number of organ systems metastases | 1 | 65 (48.8) |
2 | 38 (28.6) | |
3–4 | 30 (22.6) | |
Disease extent at breast palliative RT | Lymph node | 61 (45.9) |
Liver | 26 (19.5) | |
Lung | 59 (44.4) | |
Bone | 72 (54.1) | |
Brain | 5 (3.8) | |
Status | De novo stage IV | 30 (22.6) |
Progressive stage IV | 76 (57.1) | |
Recurrent stage IV | 27 (20.3) | |
Disease burden outside the breast | Stable disease | 104 (78.2) |
Progressive disease | 17 (12.8) | |
Mixed response | 12 (9.0) | |